Itrazol

Itraconazole, the active ingredient in Itrazol, is a azole antifungal presented as an oral formulation for systemic use. It treats a range of fungal infections including skin, nail and invasive mycoses in adult patients. GNH USA supplies Itrazol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazole is an azole antifungal used to treat infections caused by dermatophytes, yeasts and dimorphic fungi. - Dermatophytosis: eradicates skin infections caused by dermatophyte fungi. - Onychomycosis: clears fungal nail infections resistant to topical therapy. - Blastomycosis: treats systemic infection caused by Blastomyces dermatitidis. - Histoplasmosis: manages disseminated disease from Histoplasma capsulatum. - Coccidioidomycosis: resolves infection due to Coccidioides species. - Aspergillosis: combats invasive disease caused by Aspergillus spp.

Common side effects are generally mild and reversible.

Common Side Effects: - Nausea: occasional upset stomach. - Vomiting: transient episodes after dosing. - Abdominal pain: mild discomfort in the gastrointestinal tract. - Headache: occasional dull or throbbing pain. - Rash: mild skin redness or itching. - Taste disturbance: altered perception of flavors.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: worsening of pre‑existing heart conditions. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Visual disturbances: blurred vision or photophobia. - Severe hypokalemia: low potassium levels requiring monitoring.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor for adverse events. - Liver function monitoring: obtain baseline tests and repeat periodically. - Drug interaction review: evaluate concomitant medications that affect CYP3A4. - Cardiac risk assessment: avoid in patients with known heart failure. - Pregnancy consideration: use only when benefits outweigh potential risks. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Itraconazole has a high potential for pharmacokinetic interactions due to CYP3A4 inhibition and induction.

Major Interactions (Avoid): - Rifampin: markedly reduces itraconazole plasma concentrations. - St. John’s wort: induces metabolism leading to sub‑therapeutic levels. - Ketoconazole: additive hepatotoxicity when combined.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR and bleeding risk; monitor coagulation parameters. - Statins (e.g., simvastatin): increased risk of myopathy; consider dose adjustment or alternative lipid‑lowering agents.